Today's Rundown As Amgen zeroes in on cancer, neuroscience pipeline under the ax GlaxoSmithKline's RIPK1 inhibitor dead on arrival Sanifit's calcification drug hits goal in renal disease phase 2b [Sponsored] RenMab™ Mouse: a leading platform for fully human antibody generation Watch out, Amgen and Mirati. Boehringer's pan-KRAS inhibitor enters cancer clinical trials GSK tuberculosis vaccine maintains efficacy out to 3 years Ironwood spinout nosedives, plots layoffs after twin phase 2 fails Zolgensma safety scare hits Novartis again as FDA halts spinal injection trial Pear Therapeutics teams up with Ironwood for GI-focused digital therapeutics Featured Story | | | Wednesday, October 30, 2019 As Amgen rides the wave of hype and hope for its early-stage KRAS effort as well as other cancer assets in its pipeline, this is pushing out its work on neuroscience. |
|
|---|
|
| | White Paper: Rise in Targeted Therapies Biologics have experienced steady double-digit growth over the last 15 years. Precision medicine is also on the rise. Learn more about what to look for when navigating this new era of small-volume manufacturing. |
Top Stories Wednesday, October 30, 2019 Just one year ago, encouraging preclinical data saw GlaxoSmithKline kick-start a new clinical test of its investigational RIPK1 inhibitor GSK095. Now, the drug’s test in a tough-to-beat cancer has been axed. Wednesday, October 30, 2019 A phase 2b trial of Sanifit’s SNF472 in hemodialysis patients has hit its primary endpoint, teeing the Spanish biotech up to take the calcification inhibitor forward. Monday, October 28, 2019 Biocytogen uses chromosome engineering for the in situ replacement of mouse antibody genes with the human counterparts, authentic position within the chromosome. Wednesday, October 30, 2019 Amgen and Mirati Therapeutics may lead the race to develop KRAS inhibitors to treat cancer, but their candidates only target G12C-mutant tumors. Enter Boehringer Ingelheim, which has just advanced its pan-KRAS drug into clinical testing with the hopes of showing it can address around 15% of all metastatic cancers. Wednesday, October 30, 2019 GlaxoSmithKline has shared updated data from a phase 2b trial of its tuberculosis vaccine candidate M72/AS01E. Three years after vaccination, protection against active pulmonary tuberculosis disease remained up around 50%, suggesting the candidate provides lasting immunity against the bacterium. Wednesday, October 30, 2019 Ironwood spinout Cyclerion Therapeutics will lay off 30 of its 135 employees after one of its lead programs fell short in phase 2 studies in heart failure and diabetic kidney disease. The company’s stock plummeted more than 75% when trading opened on Wednesday. Wednesday, October 30, 2019 Novartis' bid to expand Zolgensma's market has suffered a setback. After a safety red flag emerged in an animal study, the FDA halted enrollment in a trial testing the gene therapy's new spinal-injection formula. At best, it's a delay for the drugmaker's plan to treat older, later-onset patients. Wednesday, October 30, 2019 Prescription digital therapeutic developer Pear Therapeutics is expanding its app-based platform to conditions outside of the brain and mental health through a gastrointestinal disease-focused collaboration with Ironwood Pharmaceuticals. | | QUALITY. SPEED. VALUE.
You Can Have All Three We deliver potent, picomolar-affinity, development-ready human antibodies in a greater number and a shorter timeline than other CROs using transgenic animals, in vitro display or humanization, including for difficult targets such a GPCRs. Contact us at info@alivamab.com to learn more. alivamab.com |
Resources Sponsored by: BBK Worldwide Get the latest data on how people are using apps to manage their health, and learn how you can leverage it in the development of your next clinical trial app. Sponsored by: Blue Latitude Health Report: How to design digital services that deliver value and improve outcomes for patients, healthcare professionals and the healthcare systems they serve Sponsored by: Article Galaxy powered by Reprints Desk This white paper examines the skyrocketing cost of drug development and provides step-by-step guidance for executing a successful fail fast strategy. Sponsored by: Outer Edge Technology Companies that don’t have a cloud strategy are at a competitive disadvantage. Why? The cloud has a measurable impact on business. Sponsored by: Medidata Simplified filing, improved oversight, audit readiness: is your eTMF system delivering best-in-class benefits? Sponsored by: Colorcon® Learn about how you better manage product authentication and battle drug counterfeiting with innovative solutions. Sponsored by: Cortellis, a Clarivate Analytics Solution Download this report for full details of Life sciences M&As in the second quarter of 2019 with notes and trends. Sponsored by: Elligo Health Research Find out how it leverages real-world data and novel IntElligo Research Stack™ technology to help researchers battle rising costs, cumbersome processes, and stagnant participation — bridging the gap between research and care. Sponsored by: InformedDNA Download this complimentary guide paper that explores key strategies for a successful genetics-informed clinical trial. Sponsored by: Life Image The time has finally come when medical imaging can be effectively utilized into the RWE process. Read the whitepaper on the best practices for incorporating Real World Imaging.™ Sponsored by: Patheon, by Thermo Fisher Scientific Is your API development on track? Sponsored by: Roche and IQVIA A global landscape study of funding trends and innovations. Sponsored by: Catalent Download the case study to learn about the clinical supply management tools that helped a small sized pharma company during phase III of a multi-arm oncology study. Sponsored by: Catalent Watch a short video on demand led supply model. It is designed to meet the needs of patients, clinical sites, clinical team and sponsors and results in shorter lead time, less waste, less stock out risk and no booklet labels. Sponsored by: Catalent Download the eBook to explore a proactive approach for clinical supply management. 4th FierceBiotech Drug Development Forum October 28-29, 2019 | Boston, MA Drug Development Immersion November 7-8, 2019 | Boston, MA Advanced Therapies: Immunotherapies, Cell Therapies and Gene Therapies November 15, 2019 | Boston, MA Countdown to Drug Development Boot Camp® 2019 November 20-21, 2019 | Boston, MA | Register Now at www.drugstomarket.com/drugbootcamp and start Pre-Boot Camp Preparation | 